热门资讯> 正文

Fate Therapeutics任命新首席财务官支持自身免疫项目扩展

2025-10-14 20:15

Fate Therapeutics (NASDAQ:FATE) has appointed Kamal Adawi as chief financial officer, effective October 20, 2025.
Adawi brings over 20 years of financial leadership experience in life sciences, including 10+ years as CFO.
Adawi's expertise aligns with Fate’s strategy to advance iPSC-derived therapies, including FT819 for lupus.

More on Fate Therapeutics

Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
Seeking Alpha’s Quant Rating on Fate Therapeutics
Historical earnings data for Fate Therapeutics
Financial information for Fate Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。